RxDoctor Payments Data

Charles Stanfield, MD

Family Medicine · Oklahoma City, OKNPI 1225091366

Payments from drug & device makers

$8,125in general payments, 2019–2025

Across 486 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Bayer$815
  • AstraZeneca$722
  • Pfizer$676
  • Boehringer Ingelheim$632
  • Amgen$597
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$8,119100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,125 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$220,236
Medicare patients
684
Services billed
2,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide275$369,427
JardianceEmpagliflozin117$152,578
OzempicSemaglutide88$114,878
EliquisApixaban78$85,830
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$56,095
XareltoRivaroxaban34$48,673
TrulicityDulaglutide24$44,070
Dupixent PenDupilumab11$39,900
JanumetSitagliptin Phos/Metformin Hcl26$33,872
Tresiba Flextouch U-200Insulin Degludec28$28,937
Synjardy XrEmpagliflozin/Metformin Hcl21$24,917
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$22,216
FarxigaDapagliflozin Propanediol13$20,543
MyrbetriqMirabegron22$18,401
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog35$17,691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,029$413,496299 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy$632$193,139155 claims
Novo NordiskOzempic$411$114,87888 claims
PfizerEliquis$676$85,83078 claims
GSKTrelegy Ellipta, Breo Ellipta$417$64,86890 claims
Johnson & JohnsonXarelto$14$48,67334 claims
MerckJanumet, Belsomra$111$39,28839 claims
AstraZenecaFarxiga$722$20,54313 claims
Astellas Pharma US IncMyrbetriq$441$18,40122 claims
AbbVieSynthroid$595$3,67857 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →